Literature DB >> 24067369

HIC1 interacts with and modulates the activity of STAT3.

Ying-Mei Lin1, Chia-Mei Wang, Jen-Chong Jeng, Dominique Leprince, Hsiu-Ming Shih.   

Abstract

HIC1 (hypermethylated in cancer 1) is a tumor suppressor gene, expression of which is frequently suppressed in human cancers. Very little is known about the molecular basis of HIC1 in antagonizing oncogenic pathways. Here, we report that HIC1 forms complexes with the signal transducers and activators of transcription 3 (STAT3) and attenuates STAT3-mediated transcription. STAT3 was identified as a HIC1-interacting protein by affinity capture and followed by mass spectrometry analysis. Overexpression or depletion of HIC1 resulted in decreased or increased levels of interleukin-6 (IL-6)/oncostatin M (OSM)-induced STAT3-mediated reporter activity and expression of target genes such as VEGF and c-Myc, respectively. Furthermore, HIC1 suppressing the VEGF and c-Myc promoter activity and the colony formation of MDA-MB 231 cells were STAT3-dependent. Further studies showed that HIC1 interacts with the DNA binding domain of STAT3 and suppresses the binding of STAT3 to its target gene promoters. Domain mapping study revealed that HIC1 C-terminal domain binds to STAT3. HIC1 mutant defective in STAT3 interaction reduced its repressive effect on STAT3 DNA binding activity, the reporter activity and gene expression of the VEGF and c-Myc genes, and cell growth in MDA-MB 231 cells. Altogether, our findings not only provide a novel role of HIC1 in antagonizing STAT3-mediated activation of VEGF and c-Myc gene expression and cell growth, but also elucidate a molecular basis underlying the inhibitory effect of HIC1 on STAT3 transcriptional potential.

Entities:  

Keywords:  DNA binding; HIC1; STAT3; protein interaction; transcriptional regulation

Mesh:

Substances:

Year:  2013        PMID: 24067369      PMCID: PMC3755077          DOI: 10.4161/cc.25365

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  53 in total

Review 1.  Inhibitors of cytokine signal transduction.

Authors:  Samuel Wormald; Douglas J Hilton
Journal:  J Biol Chem       Date:  2003-11-07       Impact factor: 5.157

Review 2.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential.

Authors:  Ding-Yen Lin; Ming-Zong Lai; David K Ann; Hsiu-Ming Shih
Journal:  J Biol Chem       Date:  2003-02-20       Impact factor: 5.157

5.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.

Authors:  J R Grandis; S D Drenning; Q Zeng; S C Watkins; M F Melhem; S Endo; D E Johnson; L Huang; Y He; J D Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

6.  An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.

Authors:  Nicolas Stankovic-Valentin; Sophie Deltour; Jacob Seeler; Sébastien Pinte; Gérard Vergoten; Cateline Guérardel; Anne Dejean; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 7.  STAT proteins: from normal control of cellular events to tumorigenesis.

Authors:  Valentina Calò; Manuela Migliavacca; Viviana Bazan; Marcella Macaluso; Maria Buscemi; Nicola Gebbia; Antonio Russo
Journal:  J Cell Physiol       Date:  2003-11       Impact factor: 6.384

8.  Identification of a nuclear Stat1 protein tyrosine phosphatase.

Authors:  Johanna ten Hoeve; Maria de Jesus Ibarra-Sanchez; Yubin Fu; Wei Zhu; Michel Tremblay; Michael David; Ke Shuai
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

Review 9.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

10.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.

Authors:  Huang Shao; Haiyun Y Cheng; Richard G Cook; David J Tweardy
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

View more
  8 in total

1.  The transcriptional repressor HIC1 regulates intestinal immune homeostasis.

Authors:  K Burrows; F Antignano; M Bramhall; A Chenery; S Scheer; V Korinek; T M Underhill; C Zaph
Journal:  Mucosal Immunol       Date:  2017-03-22       Impact factor: 7.313

2.  Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.

Authors:  Maria Teresa Di Martino; Pietro Hiram Guzzi; Daniele Caracciolo; Luca Agnelli; Antonino Neri; Brian A Walker; Gareth J Morgan; Mario Cannataro; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Oncotarget       Date:  2015-08-07

3.  The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53.

Authors:  Anette Szczepny; Kirstyn Carey; Lisa McKenzie; W Samantha N Jayasekara; Fernando Rossello; Alvaro Gonzalez-Rajal; Andrew S McCaw; Dean Popovski; Die Wang; Anthony J Sadler; Annabelle Mahar; Prudence A Russell; Gavin Wright; Rachael A McCloy; Daniel J Garama; Daniel J Gough; Stephen B Baylin; Andrew Burgess; Jason E Cain; D Neil Watkins
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

Review 4.  STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment.

Authors:  Federica Laudisi; Fabio Cherubini; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2018-06-16       Impact factor: 5.923

5.  Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/VEGF signalling pathway.

Authors:  Wen-Xiang Cheng; Huan Huang; Jian-Hai Chen; Tian-Tian Zhang; Guo-Yuan Zhu; Zheng-Tan Zheng; Jie-Tao Lin; Yi-Ping Hu; Yong Zhang; Xue-Ling Bai; Yan Wang; Zhan-Wang Xu; Bing Song; Yi-Ying Mao; Fei Yang; Peng Zhang
Journal:  J Orthop Translat       Date:  2019-08-23       Impact factor: 5.191

Review 6.  Highlighted STAT3 as a potential drug target for cancer therapy.

Authors:  Haeri Lee; Ae Jin Jeong; Sang-Kyu Ye
Journal:  BMB Rep       Date:  2019-07       Impact factor: 4.778

7.  Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.

Authors:  Ailian Xiong; Zhengduo Yang; Yicheng Shen; Jia Zhou; Qiang Shen
Journal:  Cancers (Basel)       Date:  2014-04-16       Impact factor: 6.639

8.  HIC1 links retinoic acid signalling to group 3 innate lymphoid cell-dependent regulation of intestinal immunity and homeostasis.

Authors:  Kyle Burrows; Frann Antignano; Alistair Chenery; Michael Bramhall; Vladimir Korinek; T Michael Underhill; Colby Zaph
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.